综述:评估下消化道肠-脑轴互动障碍治疗疗效的替代终点
本综述评估闪烁显像结肠传输(CT)与肠易激综合征(IBS)或慢性特发性便秘(CIC)患者报告症状终点应答率的相关性。24小时CT与复合/整体症状终点显著相关(Rs=-0.755,p=0.021),与排便频率或性状相关(48小时Rs=0.631,p=0.026),与腹痛不相关。结论认为闪烁显像CT测量满足症状结局替代终点的期望,尤其在IBS-D或IBS-C及CIC中。
要点
- 24小时CT与复合/整体症状终点显著相关(Rs=-0.755,p=0.021)。
- 48小时CT与排便频率或性状显著相关(Rs=0.631,p=0.026)。
- 24小时CT与腹痛不相关(Rs=-0.054,p=0.843)。
核心结论
- 闪烁显像CT测量满足症状结局替代终点的期望,尤其在IBS-D或IBS-C及CIC中。
研究设计与样本
- 综述纳入报告药物与安慰剂对24小时和48小时CT影响的随机对照试验(RCT)数据,提取药物与安慰剂应答比例差异,多个RCT时采用荟萃分析率,用Spearman相关分析CT差异与应答率差异的关联。
主要发现
- 24小时CT与复合/整体症状终点显著相关(Rs=-0.755,p=0.021)。
- CT与排便频率或性状相关(24小时Rs=0.506,p=0.074;48小时Rs=0.631,p=0.026)。
- 24小时CT与腹痛不相关(Rs=-0.054,p=0.843)。
- 排除阿洛司琼数据后,24小时CT与复合/整体症状终点相关未达统计学显著(Rs=-0.667,p=0.073),与腹痛不相关(Rs=0.377,p=0.419)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surrogate endpoints such as laboratory parameters that are not direct measurements of, but predict, clinical benefit are approved by regulatory agencies for initial proof of efficacy. No surrogate endpoints are approved for disorders of gut-brain interaction. AIM: To assess the correlation of scintigraphic colonic transit (CT) with response rates according to patient-reported symptom-based endpoints (composite/global symptoms, abdominal pain or stool frequency/consistency) in irritable bowel syndrome (IBS) or chronic idiopathic constipation (CIC). METHODS: We reviewed available data from, randomised controlled trials (RCTs) reporting effects on CT at 24 h and 48 h with drug versus placebo and extracted the difference in the proportions responding to drug or placebo, using rates from individual RCTs or from meta-analyses when more than one RCT existed for a drug. We analysed associations between differences (drug vs. placebo) in CT and in response rates using Spearman correlation. Additional analyses of CT at 24 h with composite/global symptom or pain endpoints were performed with exclusion of alosetron (the only drug slowing CT). RESULTS: CT at 24 h correlated significantly with composite/global symptom endpoints (Rs = -0.755, p = 0.021). CT correlated with stool frequency or consistency (at 24 h, Rs = 0.506, p = 0.074; at 48 h, Rs = 0.631, p = 0.026). CT at 24 h did not correlate with abdominal pain (Rs = -0.054, p = 0.843). With the exclusion of alosetron data, CT at 24 h was non-significantly correlated with the composite/global symptom endpoint (Rs = -0.667, p = 0.073), but not with abdominal pain (Rs = 0.377, p = 0.419). CONCLUSION: Scintigraphic CT measurement fulfils the expectation of a surrogate endpoint for symptom-based outcomes, particularly in IBS-D or IBS-C and CIC.
引用
- Camilleri M, Ford AC. Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut-Brain Interaction of Lower Gastrointestinal Tract. Aliment Pharmacol Ther. 2025. PMID: 39894943. doi:10.1111/apt.18527
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。